The diagnosis and management of von Willebrand disease: A United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

British Journal of Haematology

Volumn 167, Issue 4, 2014, Pages 453-465

  Laffan, Mike A ^a   Lester, Will ^b   O'Donnell, James S ^c   Will, Andrew ^d   Tait, Robert Campbell ^e   Goodeve, Anne ^f   Millar, Carolyn M ^a   Keeling, David M ^g   Dolan, G ^h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h UKHCDO Secretariat   (United Kingdom)

Author keywords

Diagnosis; Guideline; Management; United Kingdom Haemophilia Centre Doctors Organization; Von Willebrand

Indexed keywords

COLLAGEN; DESMOPRESSIN; GLYCOPROTEIN IB; IMMUNOGLOBULIN; PROTEIN INHIBITOR; RECOMBINANT VON WILLEBRAND FACTOR; RISTOCETIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR INHIBITOR;

ATHEROSCLEROSIS; CONTINUOUS INFUSION; DENTISTRY; DISEASE CLASSIFICATION; FAMILY ASSESSMENT; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNOADSORPTION; LETTER; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURGERY; SYSTEMATIC REVIEW; THROMBOCYTE AGGLUTINATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; VWF GENE; GENETICS; INTERNET; MEDLINE; VON WILLEBRAND DISEASES;

HUMANS; INTERNET; MEDLINE; PRACTICE GUIDELINES AS TOPIC; VON WILLEBRAND DISEASES;

EID: 84916221619     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13064     Document Type: Letter

References (87)

1. Abildgaard, C.F., Suzuki, Z., Harrison, J., Jefcoat, K. & Zimmerman, T.S. (1980) Serial studies in von Willebrand's disease: variability versus "variants". Blood, 56, 712-716.
2. Andrew, M., Paes, B., Milner, R., Johnston, M., Mitchell, L., Tollefsen, D.M. & Powers, P. (1987) Development of the human coagulation system in the full-term infant. Blood, 70, 165-172.
3. Batlle, J., Lopez-Fernandez, M.F., Fraga, E.L., Trillo, A.R. & Perez-Rodriguez, M.A. (2009) Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagulation & Fibrinolysis, 20, 89-100.
4. Berntorp, E., Abshire, T. & von Willebrand Disease Prophylaxis Network Steering Committee (2006) The von Willebrand disease prophylaxis network: exploring a treatment concept. Journal of Thrombosis & Haemostasis, 4, 2511-2512.
5. Berntorp, E., de Moerloose, P. & Ljung, R.C.R. (2010) The role of prophylaxis in bleeding disorders. Haemophilia, 16(Suppl. 5), 189-193.
6. Boadas, A., Fernandez-Palazzi, F., De Bosch, N.B., Cedeno, M. & Ruiz-Saez, A. (2011) Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Haemophilia, 17, 422-427.
7. Bohm, M., Taschner, S., Kretzschmar, E., Gerlach, R., Favaloro, E.J. & Scharrer, I. (2006) Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagulation & Fibrinolysis, 17, 39-45.
8. ®): a prospective study of 50 patients. Journal of Thrombosis and Haemostasis, 5, 1115-1124.
9. Budde, U., Metzner, H.J. & Muller, H.-G. (2006) Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Seminars in Thrombosis & Hemostasis, 32, 626-635.
10. Budde, U., Schneppenheim, R., Eikenboom, J., Goodeve, A., Will, K., Drewke, E., Castaman, G., Rodeghiero, F., Federici, A.B., Batlle, J., Perez, A., Meyer, D., Mazurier, C., Goudemand, J., Ingerslev, J., Habart, D., Vorlova, Z., Holmberg, L., Lethagen, S., Pasi, J., Hill, F. & Peake, I. (2008) Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Journal of Thrombosis & Haemostasis, 6, 762-771.
11. Cabrera, N., Moret, A., Caunedo, P., Cid, A.R., Vila, V., Espana, F. & Aznar, J.A. (2013) Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia, 19, 920-925.
12. Casari, C., Lenting, P.J., Wohner, N., Christophe, O.D. & Denis, C.V. (2013) Clearance of von Willebrand factor. Journal of Thrombosis & Haemostasis, 11(Suppl. 1), 202-211.
13. Casonato, A., Steffan, A., Pontara, E., Zucchetto, A., Rossi, C., De Marco, L. & Girolami, A. (1999) Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thrombosis and Haemostasis, 81, 224-228.
14. Castaman, G., Rodeghiero, F., Tosetto, A., Cappelletti, A., Baudo, F., Eikenboom, J.C.J., Federici, A.B., Lethagen, S., Linari, S., Lusher, J., Nishino, M., Petrini, P., Srivastava, A. & Ungerstedt, J.S. (2006) Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. Journal of Thrombosis & Haemostasis, 4, 2164-2169.
15. Castaman, G., Lethagen, S., Federici, A.B., Tosetto, A., Goodeve, A., Budde, U., Batlle, J., Meyer, D., Mazurier, C., Fressinaud, E., Goudemand, J., Eikenboom, J., Schneppenheim, R., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Pasi, J., Hill, F., Peake, I. & Rodeghiero, F. (2008) Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 111, 3531-3539.
16. Castaman, G., Tosetto, A., Federici, A.B. & Rodeghiero, F. (2011) Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thrombosis & Haemostasis, 105, 647-654.
17. Castaman, G., Goodeve, A., Eikenboom, J. & European Group on von Willebrand Disease (2013) Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica, 98, 667-674.
18. Chen, D., Tange, J.I., Meyers, B.J., Pruthi, R.K., Nichols, W.L. & Heit, J.A. (2011) Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. Journal of Thrombosis & Haemostasis, 9, 1993-2002.
19. Ciavarella, N., Schiavoni, M., Valenzano, E., Mangini, F. & Inchingolo, F. (1996) Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis, 26(Suppl. 1), 150-154.
20. Daly, M.E., Dawood, B.B., Lester, W.A., Peake, I.R., Rodeghiero, F., Goodeve, A.C., Makris, M., Wilde, J.T., Mumford, A.D., Watson, S.P. & Mundell, S.J. (2009) Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 113, 4110-4113.
21. Eikenboom, J., Van Marion, V., Putter, H., Goodeve, A., Rodeghiero, F., Castaman, G., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Schneppenheim, R., Budde, U., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F. & Peake, I. (2006) Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. Journal of Thrombosis & Haemostasis, 4, 774-782.
22. Favaloro, E.J. (2000) Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thrombosis & Haemostasis, 83, 127-135.
23. Favaloro, E.J. (2007) An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Seminars in Thrombosis & Hemostasis, 33, 727-744.
24. Favaloro, E.J., Henniker, A., Facey, D. & Hertzberg, M. (2000) Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thrombosis & Haemostasis, 84, 541-547.
25. Favaloro, E.J., Bonar, R., Chapman, K., Meiring, M. & Funk Adcock, D. (2012) Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. Journal of Thrombosis & Haemostasis, 10, 1043-1054.
26. Federici, A.B. (2008) The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia, 14(Suppl. 1), 5-14.
27. Federici, A.B., Stabile, F., Castaman, G., Canciani, M.T. & Mannucci, P.M. (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood, 92, 2707-2711.
28. Federici, A.B., Mannucci, P.M., Castaman, G., Baronciani, L., Bucciarelli, P., Canciani, M.T., Pecci, A., Lenting, P.J. & De Groot, P.G. (2009) Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood, 113, 526-534.
29. Flood, V.H., Friedman, K.D., Gill, J.C., Morateck, P.A., Wren, J.S., Scott, J.P. & Montgomery, R.R. (2009) Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. Journal of Thrombosis and Haemostasis, 7, 1832-1839.
30. Flood, V.H., Gill, J.C., Morateck, P.A., Christopherson, P.A., Friedman, K.D., Haberichter, S.L., Branchford, B.R., Hoffmann, R.G., Abshire, T.C., Di Paola, J.A., Hoots, W.K., Leissinger, C., Lusher, J.M., Ragni, M.V., Shapiro, A.D. & Montgomery, R.R. (2010) Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood, 116, 280-286.
31. Flood, V.H., Gill, J.C., Morateck, P.A., Christopherson, P.A., Friedman, K.D., Haberichter, S.L., Hoffmann, R.G. & Montgomery, R.R. (2011) Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood, 117, e67-e74.
32. Flood, V.H., Gill, J.C., Christopherson, P.A., Wren, J.S., Friedman, K.D., Haberichter, S.L., Hoffmann, R.G. & Montgomery, R.R. (2012) Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. Journal of Thrombosis and Haemostasis, 10, 1425-1432.
33. Gill, J.C., Endres-Brooks, J., Bauer, P.J., Marks, Jr, W.J. & Montgomery, R.R. (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood, 69, 1691-1695.
34. Goodeve, A., Eikenboom, J., Castaman, G., Rodeghiero, F., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Schneppenheim, R., Budde, U., Ingerslev, J., Habart, D., Vorlova, Z., Holmberg, L., Lethagen, S., Pasi, J., Hill, F., Hashemi Soteh, M., Baronciani, L., Hallden, C., Guilliatt, A., Lester, W. & Peake, I. (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).[Erratum appears in Blood. 2008 Mar 15;111(6):3299-300]. Blood, 109, 112-121.
35. Goudemand, J., Negrier, C., Ounnoughene, N. & Sultan, Y. (1998) Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Haemophilia, 4(Suppl. 3), 48-52.
36. Halimeh, S., Krumpel, A., Rott, H., Bogdanova, N., Budde, U., Manner, D., Faeser, B., Mesters, R. & Nowak-Gottl, U. (2011) Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thrombosis & Haemostasis, 105, 597-604.
37. Hamilton, A., Ozelo, M., Leggo, J., Notley, C., Brown, H., Frontroth, J.P., Angelillo-Scherrer, A., Baghaei, F., Enayat, S.M., Favaloro, E., Lillicrap, D. & Othman, M. (2011) Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thrombosis and haemostasis, 105, 501-508.
38. Hampshire, D.J., Burghel, G.J., Goudemand, J., Bouvet, L.C., Eikenboom, J.C., Schneppenheim, R., Budde, U., Peake, I.R. & Goodeve, A.C. (2010) Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica, 95, 2163-2165.
39. James, P.D. & Lillicrap, D. (2012) von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. American Journal of Hematology, 87(Suppl. 1), S4-S11.
40. James, P.D., Paterson, A.D., Notley, C., Cameron, C., Hegadorn, C., Tinlin, S., Brown, C., O'Brien, L., Leggo, J., Lillicrap, D. & Association of Hemophilia Clinic Directors of Canada(2006) Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. Journal of Thrombosis & Haemostasis, 4, 783-792.
41. James, P.D., Lillicrap, D. & Mannucci, P.M. (2013) Alloantibodies in von Willebrand disease. Blood, 122, 636-640.
42. Keeney, S., Bowen, D., Cumming, A., Enayat, S., Goodeve, A. & Hill, M. (2008) The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia, 14, 1099-1111.
43. Krizek, D.R. & Rick, M.E. (2000) A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thrombosis Research, 97, 457-462.
44. Laffan, M., Brown, S.A., Collins, P.W., Cumming, A.M., Hill, F.G.H., Keeling, D., Peake, I.R. & Pasi, K.J. (2004) The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia, 10, 199-217.
45. Lawrie, A.S., MacKie, I.J., Machin, S.J. & Peyvandi, F. (2011) Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia, 17, 252-256.
46. Lawrie, A.S., Stufano, F., Canciani, M.T., MacKie, I.J., Machin, S.J. & Peyvandi, F. (2013) A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia, 19, 338-342.
47. Lee, C.A., Chi, C., Pavord, S.R., Bolton-Maggs, P.H., Pollard, D., Hinchcliffe-Wood, A. & Kadir, R.A. (2006) The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia, 12, 301-336.
48. Leissinger, C., Becton, D., Cornell, Jr, C. & Cox Gill, J. (2001) High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia, 7, 258-266.
49. Lusher, J.M. (1998) Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP-a survey of European physicians. Haemophilia, 4(Suppl. 3), 11-14.
50. Mahieu, B., Jacobs, N., Mahieu, S., Naelaerts, K., Vertessen, F., Weyler, J., Jacquemyn, Y. & Van der Planken, M. (2007) Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagulation and Fibrinolysis, 18, 685-688.
51. Mannucci, P. (1988) Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders [see comments]. Blood, 72, 1449-1455.
52. Mannucci, P.M. (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 90, 2515-2521.
53. Mannucci, P.M. (2001) How I treat patients with von Willebrand disease. Blood, 97, 1915-1919.
54. Mannucci, P.M., Tamaro, G., Narchi, G., Candotti, G., Federici, A., Altieri, D. & Tedesco, F. (1987) Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. European Journal of Haematology, 39, 467-470.
55. Mannucci, P.M., Tenconi, P.M., Castaman, G. & Rodeghiero, F. (1992a) Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 79, 3130-3137.
56. Mannucci, P.M., And, D.B. & Cattaneo, M. (1992b) Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). British Journal of Haematology, 82, 87-93.
57. Mannucci, P., Kyrle, P., Schulman, S., Di Paola, J., Schneppenheim, R. & Cox Gill, J. (2013) Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion, 11, 533-540.
58. Marcus, P.D., Nire, K.G., Grooms, L., Klima, J. & O'Brien, S.H. (2011) The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects. Haemophilia, 17, 223-227.
59. Millar, C.M., Riddell, A.F. & Tuddenham, E.G. (2008a) Consideration of platelet function disorders in patients with reduced VWF levels. Haemophilia, 14, 1131-1132.
60. Millar, C.M., Riddell, A.F., Brown, S.A., Starke, R., MacKie, I., Bowen, D.J., Jenkins, P.V. & van Mourik, J.A. (2008b) Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thrombosis & Haemostasis, 99, 916-924.
61. Nitu-Whalley, I.C., Riddell, A., Lee, C.A., Pasi, K.J., Owens, D., Enayat, M.S., Perkins, S.J. & Jenkins, P.V. (2000) Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thrombosis & Haemostasis, 84, 998-1004.
62. O'Connor, D., Lester, W., Willoughby, S. & Wilde, J.T. (2011) Pregnancy in platelet-type VWD: a case series. Thrombosis & Haemostasis, 106, 386-387.
63. Othman, M. (2011) Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Reviews, 25, 147-153.
64. Ott, H.W., Griesmacher, A., Schnapka-Koepf, M., Golderer, G., Sieberer, A., Spannagl, M., Scheibe, B., Perkhofer, S., Will, K. & Budde, U. (2010) Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection. American Journal of Clinical Pathology, 133, 322-330.
65. Pasi, K.J., Collins, P.W., Keeling, D.M., Brown, S.A., Cumming, A.M., Dolan, G.C., Hay, C.R.M., Hill, F.G.H., Laffan, M. & Peake, I.R. (2004) Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia, 10, 218-231.
66. Pergantou, H., Xafaki, P., Adamtziki, E., Koletsi, P., Komitopoulou, A. & Platokouki, H. (2012) The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia, 18, e66-e67.
67. Preston, F.E. (1998) Assays for von Willebrand factor functional activity: a UK NEQAS survey. Thrombosis and Haemostasis, 80, 863.
68. Pruthi, R.K., Daniels, T.M., Heit, J.A., Chen, D., Owen, W.G. & Nichols, W.L. (2010) Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging. Thrombosis Research, 126, 543-549.
69. Quiroga, T., Goycoolea, M., Panes, O., Aranda, E., Martinez, C., Belmont, S., Munoz, B., Zuniga, P., Pereira, J. & Mezzano, D. (2007) High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica, 92, 357-365.
70. Ranger, A., Manning, R.A., Lyall, H., Laffan, M.A. & Millar, C.M. (2012) Pregnancy in type 2B VWD: a case series. Haemophilia, 18, 406-412.
71. Ray, J.G. (1998) DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstetrical and Gynecological Survey, 53, 450-455.
72. Rodeghiero, F., Tosetto, A., Abshire, T., Arnold, D.M., Coller, B., James, P., Neunert, C., Lillicrap, D., On Behalf Of the ISTH/SSC Joint VWF & Perinatal/Pediatric Hemostasis Subcommittees Working Group (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Thrombosis and Haemostasis, 8, 2063-2065.
73. Rydz, N. & James, P.D. (2012) The evolution and value of bleeding assessment tools. Journal of Thrombosis and Haemostasis, 10, 2223-2229.
74. Sadler, J.E. (1994) A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis & Haemostasis, 71, 520-525.
75. Sadler, J.E. (2003) Von Willebrand disease type 1: a diagnosis in search of a disease. Blood, 101, 2089-2093.
76. Sadler, J.E., Budde, U., Eikenboom, J.C.J., Favaloro, E.J., Hill, F.G.H., Holmberg, L., Ingerslev, J., Lee, C.A., Lillicrap, D., Mannucci, P.M., Mazurier, C., Meyer, D., Nichols, W.L., Nishino, M., Peake, I.R., Rodeghiero, F., Schneppenheim, R., Ruggeri, Z.M., Srivastava, A., Montgomery, R.R., Federici, A.B. & Working Party on von Willebrand Disease Classification (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis & Haemostasis, 4, 2103-2114.
77. Sakurai, Y., Shima, M., Imai, Y., Omura, S., Kirita, T. & Yoshioka, A. (2006) Successful use of recombinant factor VIII devoid of von Willebrand factor during multiple teeth extractions in a patient with type 3 von Willebrand disease. Blood Coagulation & Fibrinolysis, 17, 151-154.
78. Sanchez-Luceros, A., Meschengieser, S.S., Marchese, C., Votta, R., Casais, P., Woods, A.I., Nadal, M.V., Salviu, M.J. & Lazzari, M.A. (2003) Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagulation and Fibrinolysis, 14, 647-651.
79. Stirling, Y., Woolf, L., North, W.R., Seghatchian, M.J. & Meade, T.W. (1984) Haemostasis in normal pregnancy. Thrombosis and Haemostasis, 52, 176-182.
80. Tiede, A., Rand, J.H., Budde, U., Ganser, A. & Federici, A.B. (2011) How I treat the acquired von Willebrand syndrome. Blood, 117, 6777-6785.
81. Tosetto, A., Rodeghiero, F., Castaman, G., Goodeve, A., Federici, A.B., Batlle, J., Meyer, D., Fressinaud, E., Mazurier, C., Goudemand, J., Eikenboom, J., Schneppenheim, R., Budde, U., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F. & Peake, I. (2006) A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). Journal of Thrombosis & Haemostasis, 4, 766-773.
82. Tosetto, A., Castaman, G. & Rodeghiero, F. (2008) Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood, 111, 3998-4003.
83. Tosetto, A., Castaman, G. & Rodeghiero, F. (2013) Bleeders, bleeding rates, and bleeding score. Journal of Thrombosis and Haemostasis, 11(S1), 142-150.
84. Trigg, D.E., Stergiotou, I., Peitsidis, P. & Kadir, R.A. (2012) A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia, 18, 25-33.
85. Walker, I.D., Walker, J.J., Colvin, B.T., Letsky, E.A., Rivers, R. & Stevens, R. (1994) Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. Journal of Clinical Pathology, 47, 100-108.
86. ®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thrombosis and Haemostasis, 105, 1072-1079.
87. Zhukov, O., Popov, J., Ramos, R., Vause, C., Ruden, S., Sferruzza, A., Dlott, J. & Sahud, M. (2009) Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory. Haemophilia, 15, 788-796.